Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2017 2
2018 7
2019 4
2020 5
2021 7
2022 6
2023 2
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab for the treatment of renal cell carcinoma.
Di Bona C, Stühler V, Rausch S, Stenzl A, Bedke J. Di Bona C, et al. Among authors: stuhler v. Expert Opin Biol Ther. 2021 Sep;21(9):1157-1164. doi: 10.1080/14712598.2021.1935856. Epub 2021 Jun 3. Expert Opin Biol Ther. 2021. PMID: 34042015 Review.
Enfortumab vedotin - next game-changer in urothelial cancer.
Maas M, Stühler V, Walz S, Stenzl A, Bedke J. Maas M, et al. Among authors: stuhler v. Expert Opin Biol Ther. 2021 Jul;21(7):801-809. doi: 10.1080/14712598.2021.1865910. Epub 2020 Dec 27. Expert Opin Biol Ther. 2021. PMID: 33325754 Review.
Nicotinamide-N-methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma.
Reustle A, Menig LS, Leuthold P, Hofmann U, Stühler V, Schmees C, Becker M, Haag M, Klumpp V, Winter S, Büttner FA, Rausch S, Hennenlotter J, Fend F, Scharpf M, Stenzl A, Bedke J, Schwab M, Schaeffeler E. Reustle A, et al. Among authors: stuhler v. Clin Transl Med. 2022 Jun;12(6):e883. doi: 10.1002/ctm2.883. Clin Transl Med. 2022. PMID: 35678045 Free PMC article.
A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.
Büttner FA, Winter S, Stühler V, Rausch S, Hennenlotter J, Füssel S, Zastrow S, Meinhardt M, Toma M, Jerónimo C, Henrique R, Miranda-Gonçalves V, Kröger N, Ribback S, Hartmann A, Agaimy A, Stöhr C, Polifka I, Fend F, Scharpf M, Comperat E, Wasinger G, Moch H, Stenzl A, Gerlinger M, Bedke J, Schwab M, Schaeffeler E. Büttner FA, et al. Among authors: stuhler v. Genome Med. 2022 Sep 15;14(1):105. doi: 10.1186/s13073-022-01105-y. Genome Med. 2022. PMID: 36109798 Free PMC article.
31 results